DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
China · Delayed Price · Currency is CNY 18.55
+0.06 (0.32%)
May 8, 2026, 3:00 PM CST
SHA:603233 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 1,410 | 1,359 | 914.75 | 1,166 | 1,036 | 791.23 |
Depreciation & Amortization | 1,547 | 1,547 | 1,584 | 1,448 | 1,288 | 1,149 |
Other Amortization | 247.42 | 247.42 | 311.36 | 248.28 | 243.75 | 218.08 |
Loss (Gain) From Sale of Assets | -14.7 | -14.7 | -19.21 | -3.43 | -18.73 | -5.63 |
Asset Writedown & Restructuring Costs | 82.89 | 82.89 | 38.6 | 6.21 | - | - |
Loss (Gain) From Sale of Investments | -0.33 | -0.33 | -11.57 | -10.94 | 12.89 | -44 |
Provision & Write-off of Bad Debts | - | - | 15.28 | 15.92 | 23.6 | 11.49 |
Other Operating Activities | -641.13 | 210 | 347.74 | 388.19 | 294.24 | 247.49 |
Change in Accounts Receivable | 304.37 | 304.37 | -1,588 | -364.73 | -953.44 | -317.98 |
Change in Inventory | -40.93 | -40.93 | 126.08 | -104.16 | -157.39 | -745.93 |
Change in Accounts Payable | 1,641 | 1,641 | 1,395 | 389.07 | 1,967 | 235.18 |
Change in Other Net Operating Assets | - | - | 3.28 | 19.04 | 48.54 | 65.63 |
Operating Cash Flow | 4,550 | 5,350 | 3,106 | 3,174 | 3,757 | 1,555 |
Operating Cash Flow Growth | 24.74% | 72.24% | -2.13% | -15.51% | 141.58% | -20.42% |
Capital Expenditures | -512.84 | -484.84 | -1,476 | -1,797 | -1,035 | -1,295 |
Sale of Property, Plant & Equipment | 31.42 | 29.36 | 28.53 | 14.64 | 37.37 | 21.61 |
Cash Acquisitions | -103.63 | -93.97 | -520.82 | -502.3 | -305.25 | -529.82 |
Divestitures | - | - | 1.59 | - | - | - |
Investment in Securities | -163.51 | -421.85 | 11.34 | -2.16 | 5.54 | 814.11 |
Other Investing Activities | 1.69 | 0.99 | 15.86 | -11.8 | 3.17 | 21.35 |
Investing Cash Flow | -746.87 | -970.32 | -1,939 | -2,303 | -1,294 | -967.7 |
Short-Term Debt Issued | - | - | 191.88 | 16 | - | - |
Long-Term Debt Issued | - | 893.31 | 3,137 | 1,094 | 1,095 | 145.63 |
Total Debt Issued | 652.46 | 893.31 | 3,329 | 1,110 | 1,095 | 145.63 |
Short-Term Debt Repaid | - | - | - | -4.9 | - | - |
Long-Term Debt Repaid | - | -2,426 | -3,422 | -2,388 | -1,655 | -1,321 |
Total Debt Repaid | -1,933 | -2,426 | -3,422 | -2,392 | -1,655 | -1,321 |
Net Debt Issued (Repaid) | -1,280 | -1,533 | -92.44 | -1,282 | -560.15 | -1,175 |
Issuance of Common Stock | - | - | - | - | - | 13.25 |
Repurchase of Common Stock | - | - | -101.8 | -0.95 | -0.11 | -0.44 |
Common Dividends Paid | -778.45 | -782.1 | -753.21 | -604.51 | -420.29 | -534.28 |
Other Financing Activities | -1,358 | -1,383 | 15.52 | 238.15 | 46.98 | 84.37 |
Financing Cash Flow | -3,417 | -3,698 | -931.93 | -1,649 | -933.57 | -1,612 |
Foreign Exchange Rate Adjustments | -0.7 | -0.7 | 0.32 | - | - | - |
Net Cash Flow | 385.79 | 681.49 | 235.37 | -778.78 | 1,529 | -1,025 |
Free Cash Flow | 4,037 | 4,865 | 1,630 | 1,377 | 2,722 | 260.05 |
Free Cash Flow Growth | 68.99% | 198.40% | 18.39% | -49.40% | 946.64% | -77.61% |
Free Cash Flow Margin | 14.67% | 17.69% | 6.15% | 5.61% | 12.81% | 1.55% |
Free Cash Flow Per Share | 3.54 | 4.25 | 1.44 | 1.22 | 2.39 | 0.23 |
Cash Income Tax Paid | 1,325 | 1,394 | 1,268 | 1,108 | 939.01 | 897.77 |
Levered Free Cash Flow | 3,462 | 4,287 | 2,078 | 2,261 | 2,191 | 412.54 |
Unlevered Free Cash Flow | 3,463 | 4,287 | 2,234 | 2,411 | 2,336 | 545.07 |
Change in Working Capital | 1,919 | 1,919 | -74.19 | -84.49 | 876.98 | -812.84 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.